Publication | Open Access

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

First-line TherapyMedicinePathologyImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyLung CancerPhase 3